About 32 results found for searched term "Insulin Receptor" (0.089 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M50424 | [pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153) | Insulin Receptor |
| [pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153) binds to insulin and can be used as insulin receptor tyrosine kinase substrates. | ||
| M54225 | Insulin receptor (1142-1153), pTyr1150 | Others |
| Insulin receptor (1142-1153), pTyr1150 is a biological active peptide. | ||
| M1792 | XL228 | IGF-1R |
| XL-228 | ||
| XL228 is a potent multikinase small-molecule inhibitor of insulin-like growth factor type 1 receptor (IGF1R). | ||
| M1821 | OSI-906 | IGF-1R |
| Linsitinib | ||
| OSI-906 (Linsitinib) is a potent, selective, dual ATP-competitive tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with IC50 values of 35 nM and 75 nM respectively. | ||
| M1932 | GSK1838705A | ALK |
| GSK1838705A is a small-molecule kinase inhibitor that inhibits IGF-IR and the insulin receptor with IC50s of 2.0 and 1.6 nmol/L, respectively. | ||
| M1957 | BMS-536924 | IGF-1R |
| Bms-536924 is an orally active, competitive and selective insulin-like growth factor receptor (IGF-1R) kinase and insulin receptor (IR) inhibitor with IC50 of 100 nM and 73 nM, respectively. It also showed moderate inhibitory activity against Mek, Fak and Lck, but almost no inhibitory activity against Akt1 and MAPK1/2. | ||
| M2025 | PQ401 | IGF-1R |
| PQ-401 | ||
| PQ401 is an insulin growth factor-1 receptor (IGF-1R) inhibitor. PQ401 inhibits IGF-I-stimulated IGF-IR autophosphorylation with an IC50 of 12.0 μM in a series of studies in MCF-7 cells. PQ401 is effective at inhibiting IGF-I-stimulated growth of MCF-7 cells (IC50, 6 μM). | ||
| M2301 | NVP-TAE226 | FAK |
| TAE226 | ||
| Nvp-tae 226 (TAE226) is a potent atP-competitive dual FAK and IGF-1R inhibitor with IC50 of 5.5 nM and 140 nM, respectively. Nvp-tae 226 (TAE226) also effectively inhibited Pyk2, insulin receptor (InsR), with IC50 of 3.5 nM and 40 nM. | ||
| M4598 | Rhoifolin | Insulin Receptor |
| RhoifolinRhoifolin is a flavonoid glycoside isolated from the leaves of Guanxi pomelo (Citrus Grandis). Rhoifolin is beneficial to diabetic complications by enhancing adiponectin secretion, tyrosine phosphorylation of insulin receptor-β and translocation of GLUT4. Rhoifolin ameliorates titanium-stimulated osteolysis and attenuates osteoclast formation through ranKL-induced NF-κB and MAPK pathways. | ||
| M5940 | Rosiglitazone HCl | PPAR |
| BRL-49653 HCl | ||
| Rosiglitazone HCl is a hypoglycemic compound that stimulates insulin secretion by binding to PPAR receptors in fat cells. | ||
| M6291 | 5-Iodotubercidin | PKA |
| NSC 113939, 5-ITu | ||
| 5-IOdotubercidin (NSC 113939), an ATP analogue, is a potent inhibitor of adenosine kinase with an IC50 value of 26 nM. 5-IOdotubercidin (NSC 113939) initiates glycogen synthesis in isolated hepatocytes by activating phosphorylase and glycogen synthase. 5-IOdotubercidin (NSC 113939) also inhibits CK1, insulin receptor tyrosine kinase, phosphorylase kinase, PKA, CK2, PKC, and Haspin inhibitors. | ||
| M7067 | NVP ADW 742 | IGF-1R |
| ADW742; GSK 552602A; ADW | ||
| Nvp-adw742 (ADW742) is an orally active, selective igF-1R tyrosine kinase inhibitor with an IC50 of 0.17 μM. Nvp-adw742 inhibited insulin receptor (InsR) with IC50 of 2.8 μM. Nvp-adw742 induces multipotent anti-proliferation/pro-apoptosis in tumor cells. | ||
| M9487 | Tirzepatide hydrochloride | GLP Receptor |
| LY3298176 hydrochloride | ||
| Tirzepatide Hydrochloride is a glucose-dependent insulin-stimulating peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. | ||
| M8366 | DDN | Others |
| DDN (5,8-Diacetyloxy-2,3-dich |
||
| M10285 | MID-1 | Others |
| MID1 | ||
| MID-1 is an inhibitor of MG53-IRS-1 (Mitsugumin 53-Insulin Receptor Substrate-1) interaction. | ||
| M11097 | Uralenol | Phosphatase |
| Uralenol is a natural PTP1B inhibitor (IC50=21. 5 μM) from Broussonetia papyrifera. In many cellular and biochemical studies, PTP1B have been shown to play a major role in the dephosphorylation of the insulin receptor. | ||
| M11317 | S961 TFA | Insulin Receptor |
| S961 TFA is A high affinity insulin receptor (IR) antagonist with IC50 of 0.048 for HIR-A, HIR-B and higF-IR, respectively. 0.027 and 630 nM. | ||
| M11329 | AGL-2263 | Insulin Receptor |
| Agl-2263 is an inhibitor of insulin receptor and insulin-like growth factor (IGF) receptor. | ||
| M14904 | S961 acetate | Insulin Receptor |
| S961 acetate is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively. | ||
| M20011 | D-Mannitol (cell culture, ≥99.0%) | Cell Culture |
| Mannitol; Mannite | ||
| D-Mannitol is an osmotic diuretic agent and a weak renal vasodilator. In microbiology: Mannitol is a good medium for certain microorganisms. D-Mannitol can enhance brown fat formation, improve insulin effect, reduce blood sugar levels, And through the start the β3-adrenergic receptor (β3-AR), PGC1α and PKA induced by means of white fat cells into brown fat cells. | ||
| M20615 | NT157 | IGF-1R |
| NT157, a selective inhibitor of IRS-1/2(insulin receptor substrate), has the potential to inhibit IGF-1R and STAT3 signaling pathways in cancer cells and stroma cells of TME leading to a decrease in cancer cell survival. | ||
| M21631 | Recombinant Human IGF-I (E.coli, 67AA) | Cytokines and Growth Factors |
| Insulin-Like Growth Factor I; IGF1; Mecasermin | ||
| Insulin-like growth factor I (IGF1) binds IGF-1R, IGF-2R, and the insulin receptor and plays a key role in cell cycle progression, cell proliferation and tumor progression. Measured in a serum-free cell proliferation assay using MCF‑7 human breast cancer cells. The ED50 for this effect is 20-100 ng/ml. | ||
| M21721 | Recombinant Mouse IGF-I Protein (E. coli) | Cytokines and Growth Factors |
| Insulin-like Growth Factor I | ||
| Recombinant Mouse IGF-I belongs to the IGF family of peptides, which also includes IGF-II and insulin. IGF-I executes its functions via signaling through transmembrane tyrosine receptors (IGF Receptors). ED50 < 10.0 ng/ml, measured by a cell proliferation assay using FDC-P1 cells, corresponding to a specific activity of > 1.0 × 105 units/mg. | ||
| M22472 | Insulin degludec | Insulin Receptor |
| Insulin degludec is an ultra-long-acting form of insulin, shows binding efficiency with an IC50 value of 19.59 nM/L for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes. | ||
| M24820 | Valanafusp alfa | Insulin Receptor |
| AGT-181; HIRMAb-IDUA | ||
| Valanafusp alfa (AGT-181) is a brain penetrating recombinant fusion protein of a chimeric monoclonal antibody against the human insulin receptor (HIR) and human iduronidase (IDUA). Valanafusp alfa can be used for the research of Mucopolysaccharidosis type I (MPS I) . | ||
| M24933 | Insulin efsitora alfa | Insulin Receptor |
| LY-3209590 | ||
| Insulin efsitora alfa (LY-3209590) is a selective agonist of insulin receptor (IR). Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes. | ||
| M25276 | Ganitumab | IGF-1R |
| AMG 479; Human Anti-IGF1R Recombinant Antibody | ||
| Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer. | ||
| M25294 | Robatumumab | IGF-1R |
| Sch 717454; 19D12 | ||
| Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research. | ||
| M25296 | Figitumumab | IGF-1R |
| CP-751871 | ||
| Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM. | ||
| M27783 | I-OMe-Tyrphostin AG 538 | IGF-1R |
| I-OMe-AG 538 | ||
| I-OMe-Tyrphostin AG 538 (I-OMe-AG 538) is a specific inhibitor of IGF-1R (insulin-like growth factor-1 receptor tyrosine kinase). I-OMe-Tyrphostin AG 538 inhibits IGF-1R-mediated signaling and is preferentially cytotoxic to nutrient-deprived PANC1 cells. I-OMe-Tyrphostin AG 538 is an ATP-competitive inhibitor of phosphatidylinositol-5-phosphate 4-kinase α (PI5P4Kα), with an IC50 of 1 µM. | ||
| M27849 | ITK antagonist | Itk |
| ITK antagonist (compound 10 n) is a potent, orally active and selective ITK (Interleukin-2 inducible T-cell kinase) antagonist (IC50=1 and 20 nM in different assays). ITK antagonist inhibits insulin receptor kinase (IRK) with an IC50 of 160 nM. | ||
| M27918 | NT219 | Insulin Receptor |
| NT219 is a potent and dual inhibitor of insulin receptor substrates 1/2 (IRS1/2) and STAT3. IRS1/2 and STAT3 are major signaling junctions regulated by various oncogenes. NT219 affects IRS1/2 degradation and inhibits STAT3 phosphorylation. NT219 has the potential for the research of cancer diseases. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
